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A B S T R A C T
Insulin modulates dopamine neuron activity in midbrain and affects processes underlying food intake behaviour, including impulsivity and reward processing. Here,
we used intranasal administration and task-free functional MRI in humans to assess time- and dose-dependent effects of insulin on functional connectivity of the
dopaminergic midbrain – and how these effects varied depending on systemic insulin sensitivity as measured by HOMA-IR. Speciﬁcally, we used a repeated-measures
design with factors dose (placebo, 40 IU, 100 IU, 160 IU), time (7 time points during a 90min post-intervention interval), and group (low vs. high HOMA-IR).
A factorial analysis identiﬁed a three-way interaction (with whole-brain signiﬁcance) with regard to functional connectivity between midbrain and the ventro-
medial prefrontal cortex. This interaction demonstrates that systemic insulin sensitivity modulates the temporal course and dose-dependent effects of intranasal insulin
on midbrain functional connectivity. It suggests that altered insulin sensitivity may impact on dopaminergic projections of the midbrain and might underlie the
dysregulation of reward-related and motivational behaviour in obesity and diabetes. Perhaps most importantly, the time courses of midbrain functional connectivity
we present may provide useful guidance for the design of future human studies that utilize intranasal insulin administration.
1. Introduction
Most previous studies on the neural control of feeding behaviour
focused on signalling mechanisms associated with the regulation of body
weight homeostasis. Apart from impaired cerebral regulation of meta-
bolic homeostasis, additional cognitive and affective factors can inﬂu-
ence eating behaviour and induce excessive weight gain (Begg and
Woods, 2013; Ferrario et al., 2016; Medic et al., 2016). In particular,
observations that food anticipation and intake trigger dopaminergic re-
sponses that are modulated by diet and body weight (de Araujo et al.,
2008; Medic et al., 2014; Stice et al., 2009, 2010; Wang et al., 2014) raise
the question how homeostatic signals interact with dopaminergic neu-
rocircuitry that is involved, amongst other processes, in reward pro-
cessing and impulsivity (Buckholtz et al., 2010; Kenny, 2011b; Volkow
et al., 2011).
Insulin is a key candidate for mediating this interaction. It represents
a critical hormone for metabolic regulation but also impacts on
dopamine-dependent processes (Lockie and Andrews, 2013): both
hyperinsulinemia and insulin resistance have been associated with mal-
adaptive eating behaviour (Heni et al., 2015; Kleinridders et al., 2015;
K€onner and Brüning, 2012; Morton et al., 2014) and brain disorders
involving dopaminergic transmission (Athauda and Foltynie, 2016). As a
consequence, the question how insulin may regulate dopaminergic
transmission is increasingly moving into the focus of studies onmetabolic
control.
Insulin receptors (IR) are expressed by neurons in numerous brain
regions (Kleinridders et al., 2014; Plum et al., 2005). Remarkably, the
major sources of dopaminergic (DA) neurons – the ventral tegmental area
(VTA) and the substantia nigra (SN) in the midbrain (Morales and
Margolis, 2017) – are particularly enriched in insulin receptors (IR,
Figlewicz et al., 2003). Here, the IR is co-expressed with tyrosine hy-
droxylase (Th), a key enzyme and marker for catecholaminergic neurons.
Th neuron-speciﬁc deletion of the IR was shown to result in a reduction of
excitatory input on DA VTA/SN neurons (Figlewicz et al., 2003).
Furthermore, K€onner et al. (2011) demonstrated that insulin has a sig-
niﬁcant excitatory effect on a major subpopulation of DA VTA/SN neu-
rons: it increases the ﬁring rate of these DA neurons but also upregulates
DA clearance via increased trafﬁcking of DA reuptake transporters (DAT;
Mebel et al., 2012) and higher DAT-mRNA expression (Figlewicz et al.,
2007). This increased insulin-mediated DA clearance may contribute to
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enhanced DA neuron excitability via reduced activation of inhibitory D2
autoreceptors on DA VTA/SN cells (Uchida et al., 2000). Finally, insulin
induces long-term depression of excitatory synapses on VTA dopamine
neurons by endocannabinoid signalling (Labouebe et al., 2013), a
mechanism that is attenuated by hyperinsulinemia (Liu et al., 2013).
This set of insulin actions on DA neurons provides a potential link
between the control of food intake and processes associated with dopa-
minergic circuitry and transmission (Figlewicz et al., 2007; Figlewicz and
Sipols, 2010; Palmiter, 2007). For example, insulin modulates reward
seeking and drug relapse – behaviours associated with DA signalling in
the mesolimbic dopamine system (Davis et al., 2010; Figlewicz and
Benoit, 2009; Kenny, 2011a). Furthermore, direct insulin application in
the VTA reduces intracranial self-stimulation and food intake (Bruijnzeel
et al., 2011), and the consumption of sweetened high fat food can be
decreased by insulin in the VTA (Mebel et al., 2012). In summary,
numerous preclinical studies suggest that insulin action on DA neurons
contributes to energy maintenance and consumption behaviour by
adjusting the reward value of food items (Figlewicz et al., 2007). Inter-
estingly, Bruijnzeel et al. (2011) found that this effect is dose-dependent.
While low doses of insulin in the VTA modulated the reward threshold,
higher doses reduced food intake but did not change reward-related
behaviour.
Despite these exciting ﬁndings, much remains to be learned about the
detailed mechanism(s) of how insulin controls DA neuron excitability,
and importantly, how insulin affects the dopaminergic circuitry in
humans. Clearly, elucidating these mechanisms in detail is of great
importance, both for understanding the role of the DA system in the
development of obesity – e.g., body mass index is negatively correlated
with dopamine receptor D2 (D2R) density in striatal regions (Volkow
et al., 2008; Wang et al., 2001) – and for understanding how interactions
between DA and insulin modulate non-homeostatic eating behaviour in
general. Furthermore, given that interactions between mechanisms
amplify the variability of jointly affected outcomes, the interaction be-
tween hormonal and neuromodulatory mechanisms may be key to un-
derstanding individual variability in eating behaviour and suggest new
therapeutic strategies against obesity.
In humans, intranasal administration is the method of choice to study
insulin effects on neuronal processes without relevant systemic side ef-
fects. Initial studies demonstrated a wide range of functional conse-
quences from intranasal insulin application in humans (cf. Suppl.
Table S1, for a collection of currently available reports), including
reduced food intake both after single administration (Hallschmid et al.,
2012; Jauch-Chara et al., 2012) and long-term application (Hallschmid
et al., 2004). In line with animal studies, postprandial application in
humans reduced the consumption of palatable food and increased satiety
(Hallschmid et al., 2012). Functional magnetic resonance imaging
studies (fMRI) investigated insulin effects on the response to food cues or
at rest, showing modulation of neural activity in brain areas typically
associated with food intake and reward behaviour (Guthoff et al., 2010;
Kullmann et al., 2013, 2015; Schilling et al., 2014; Tiedemann et al.,
2017; Zhang et al., 2015). In addition, a recent genetic imaging study
suggested a relevant interaction between intranasally applied insulin and
D2R availability (Heni et al., 2016).
These initial ﬁndings are not easily interpretable, since we lack
knowledge about the pharmacokinetics of intranasally applied insulin in
general and about the time course and dose-dependency of its modula-
tory effect on the midbrain in particular. So far, the only study on the
pharmacokinetics of intranasally applied insulin used a single dose (40
I.U., Born et al., 2002) and was conducted invasively (via lumbar punc-
ture). This study found peak insulin levels in the cerebrospinal ﬂuid (CSF)
30min after intranasal insulin application. However, peak insulin accu-
mulation in the CSF does not correspond to peak neuronal effects, nor
does it provide information about insulin action on midbrain activity or
connectivity. Relying on the report by Born et al. (2002), most recent
studies tested central effects of intranasal insulin 30min after adminis-
tration of 40 I.U. or 160 I.U (Suppl. Table S1). It remains unclear,
however, which dose is effective to modulate dopaminergic processes
and at which time point after intranasal application neurons respond.
To ﬁll this gap of knowledge and assess the time- and dose-dependent
effects of insulin on dopaminergic transmission, we designed a ran-
domized, placebo-controlled pharmacological fMRI study with a within-
subject (crossover) design. We investigated the effect of intranasal
administration of insulin under three commonly used doses (40, 100 and
160 I.U.), taking six measurements during a time period of 15–90min
after application. As a proxy for a readout of dopaminergic transmission,
we measured the functional connectivity of the dopaminergic midbrain
(VTA/SN) with the rest of the brain. Given that insulin in the brain in-
ﬂuences food intake and body weight in lean persons (Heni et al., 2015)
and no such effect has yet been observed in overweight individuals
(Hallschmid et al., 2008; Heni et al., 2017), we predicted that
insulin-dopamine interactions may change with BMI. We therefore
examined two groups, i.e., individuals with normal weight and over-
weight. Interestingly, we could not ﬁnd an insulin-dopamine interaction
with BMI. Hence, we analysed the insulin-dopamine interaction with
peripheral insulin sensitivity assessed by the homeostasis model assess-
ment of insulin resistance (HOMA-IR, McAuley et al., 2007). It is
important to note that none of these subjects were obese or suffered from
diabetes.
2. Materials and methods
Participants. Twenty-one subjects of normal weight (22.4 kg/
m2 1.7) as well as twenty-one overweight subjects (28.0 kg/m2 4.0)
were recruited from the pre-existing database of volunteers maintained
at the Max-Planck-Institute for Metabolic Research. All participants were
medication-free and male. We only employed male participants to
exclude variations of hormonal effects on the BOLD signal during the
menstrual cycle. All participants were non-smokers without any history
of neurological, psychiatric, gastrointestinal or eating disorders, and
without any special diets or medical treatments. To exclude athletes
whose BMI would, due to increased muscle mass, falsely classify them as
overweight, we included only participants who indicated that they do not
engage in high-intensity physical workout. In the course of data analysis,
six subjects had to be excluded: three subjects due to malfunction of the
MR scanner, one showed strong motion artefacts in the placebo condi-
tion, one had a signiﬁcantly enhanced cortisol level during the baseline
condition of the placebo day compared to all other testing days and one
subject signiﬁcantly lost weight (3,4 kg) during the study. In total, 17
lean (BMI: 22.9 kg/m2 1.5, age: 27.0 yrs4.0) and 19 overweight
subjects (7.2 kg/m2 1.5, age: 30.0 yrs4.9) were included in further
data analyses (Table 1). After analysing the effects of group stratiﬁed by
body weight (normal vs. overweight), we considered to scrutinize how
insulin-dopamine interactions in the brain may change with systemic
insulin resistance. Hence, subjects were classiﬁed for the analysis into
two groups, i.e., individuals with higher and lower peripheral insulin
sensitivity assessed by the homeostasis model assessment of insulin
resistance (HOMA-IR, Matthews et al., 1985; McAuley et al., 2007). To
that end, HOMA-IR was calculated as (fasting serum glucose in
mg/dl fasting serum insulin in mU/l)/405, with lower values indi-
cating a higher degree of insulin sensitivity. The subjects were separated
Table 1
Participant characterization (mean standard deviation).
Parameter low HOMA-IR high HOMA-IR
n 19 17
Age 29.51 (4.58) 27.77 (4.51)
BMI 25.23 (2.81) 25.09 (2.50)
HOMA-IRa 1.07 (0.23) 2.44 (1.02)
BDI 3.32 (3.54) 3.35 (2.47)
BIS 58.16 (7.35) 59.18 (8.60)
a Acquired during baseline condition on the testing day, when placebo was
applied.
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into a low and high HOMA-IR group based on the HOMA-IR values in
baseline condition; the threshold was set to 1.5 using a median split. Two
participants did have a median HOMA-IR, these were assigned arbitrarily
to the lower HOMA-IR group. All participants gave written informed
consent to participate in the experiment, which was approved by the
local ethics committee of the Medical Faculty of the University of Co-
logne (Cologne, Germany).
Experimental design. The study was carried out in a single-blinded,
placebo-controlled, randomized, crossover design (Fig. 1). Each volun-
teer participated on four testing days that were 4–21 days apart and
started around the same time of the day (either at 8:00 a.m. or 10:00
a.m.). On each testing day, participants arrived fasted with the last meal
before 10 p.m. of the previous day.
Each participant received, on different days, either 40, 100 or 160
units of insulin (I.U.; Huminsulin® Normal KwikPen 100 I.U./ml; Lilly
Germany GmbH) or 1ml of placebo (Saline KwikPen, Lilly Germany
GmbH) in a counterbalanced order. As placebo, the vehicle solution was
used that would normally contain the insulin and was, hence, indistin-
guishable by smell or sensation from insulin. To directly reach the central
nervous system and circumvent the blood brain barrier the intervention
was administered intranasally. Insulin and placebo were administered
with a precision air pump (Aero Pump, Hochheim, Germany) alternating
between both nostrils with an interval of 1min to allow sufﬁcient time
for absorption. Each puff of the air pump contained 0.1 ml of solution
(equal to 10 I.U.).
On each testing day, prior to subjects' placement in the scanner, an
intravenous catheter was inserted into the left forearm vein. The imaging
study started with a 10-min task-free fMRI scan (baseline scan). Post-
intervention scans were divided into two blocks entailing three 10min
functional runs per block – the ﬁrst block starting 15min after the
intervention, the second 60min post-intervention. Subjects were
instructed not to sleep, to lie still and to focus their attention on a dark
screen with a central ﬁxation cross. A pulsoxymeter at the left index
ﬁnger and a ﬂexible pressure belt on their chest were used to record heart
rate and respiration rate. Blood samples were drawn before each baseline
scan as well as 10, 50, and 90min post-intervention; glucose, insulin and
c-peptide level were measured to control for systemic effects of the
intranasally administered insulin. Before the start of each block subjects
were asked to rate their hunger, satiety and tiredness on a continuous
100-mm visual analogue scale (0¼ “very hungry/sated/tired” and
100¼ “not hungry/sated/tired at all”). At the end of each testing day,
subjects were further asked to rate whether they received insulin or
placebo and to indicate the putative dose on a 100-mm visual analogue
scale (0¼ low dose, 100mm¼ high dose).
Additionally, on the ﬁrst testing day subjects received a standardized
breakfast (one piece of white toast with a slice of cheese or ham) after
completing MR-acquisition and blood sampling. To avoid possible
hunger-dependent bias the breakfast was provided before the subjects
ﬁlled in a set of questionnaires comprising the Beck Depression Inventory
(BDI-II, Beck et al., 1996) and the Baratt Impulsiveness Scale (BIS-11,
Patton et al., 1995).
Imaging parameters. All imaging was performed on a 3T MRI system
(Siemens Magnetom Prisma, Erlangen, Germany). Functional imaging
data were acquired using a task-free paradigm (“resting state”), lasting
10 min for each of the seven measurements. We used a 64-channel head
coil (Siemens, Erlangen, Germany) and 30 axial slices with a T2*-
weighted echo-planar imaging sequence (slice thickness: 2 mm; in-
plane resolution: 2 mm  2 mm; no distance factor; ascending inter-
leaved in-plane acquisition; TR ¼ 2000 ms; TE ¼ 30 ms; ﬂip angle ¼ 90;
ﬁeld of view ¼ 192  192  60 mm3; PAT factor¼ 2). After each fMRI
block a short anatomical scan was performed ﬁrst (MPRAGE: 30 slices,
voxel size 2 2 2mm3, 192 192mm ﬁeld of view, 250ms repetition
Fig. 1. Placebo-controlled, randomized, crossover design: All volunteers participated on four testing days after an overnight fast. In the baseline condition a blood
draw was taken and subjects were asked to rate on hunger, satiety and tiredness before they underwent a 10-min baseline scan. Thereafter, either 40 I.U., 100 I.U. or
160 I.U. of insulin or placebo was intranasally administered in a randomized order. Blood samples and ratings on the internal state were acquired 10, 50, and 90min
post-intervention. We acquired two blocks of task-free fMRI data with three 10-min runs each: The ﬁrst block covered the interval of 15–45min, the second one the
period of 60–90min after intervention.
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time (TR), 2,86ms echo time (TE), 0% distance factor), then high-
resolution T1-weighted images were acquired using a 12-channel array
head coil with 128 sagittal slices that covered the whole brain
(MDEFT3D: TR¼ 1930ms, TI¼ 650ms, TE¼ 5.8ms, resolution
1 1 1.25mm3, ﬂip angle 18).
Data analysis. The individual data sets were preprocessed before
running statistical analyses using tools from the FMRIB Software Library
(FSL version 5.08, www.fmrib.ox.ac.uk/fsl) and according to Smith et al.
(2013): Time series were ﬁrst realigned to correct for small head move-
ments (Jenkinson et al., 2002). Non-brain tissues (e.g., scalp and CSF)
were removed using an automated brain extraction tool (Smith, 2002).
Data were spatially smoothed using a 6 mm Gaussian FWHM kernel.
High-pass temporal ﬁltering was applied (FWHM ¼ 100 s). Structured
artefacts were then removed using independent component analysis
followed by FSL's ICA-based X-noiseiﬁer (ICA þ FIX; Griffanti et al.,
2014; Salimi-Khorshidi et al., 2014). Then, functional data were
co-registered to the subject's T1-weighted image and normalized to
standard space (MNI152, voxel size 1 1 1mm3).
Subsequently, statistical data analysis was carried out by using sta-
tistical parametric mapping (SPM12; Wellcome Centre for Human Neu-
roimaging, London) in MATLAB (version 2014b, The MathWorks). This
analysis proceeded in two steps: (i) determining subject- and session
(time point) -speciﬁc functional connectivity of the midbrain; (ii) testing
for the effects of time, dose, and either BMI or HOMA-IR on midbrain
connectivity.
Subject- and time point-speciﬁc functional connectivity. We speciﬁed a
voxel-wise general linear model (GLM) for each subject comprising
intervention dose and time point (resulting in 4 7 separate GLMs per
subject). As regressor of interest, these GLMs included the time series of
the VTA/SN which was deﬁned anatomically using a mask based on
previous magnetization transfer weighted MR images (Bunzeck and
Düzel, 2006). Additional regressors of no interest accounted for potential
confounds: the six realignment parameters (representing head motion),
and two time series from the CSF and white matter, respectively.
The voxel-wise parameter estimates for our regressor of interest
represent a linear measure of functional coupling, i.e. the coefﬁcient
obtained from regressing the VTA/SN time series on the time series of the
respective voxel. In other words, we examined functional connectivity
values that reﬂected the speciﬁc effect of insulin over time in the same
subject. These subject-, intervention dose- and session-speciﬁc contrast
images were then entered into a second-level (group-level) GLM.
Group analyses of functional connectivity. To investigate the pharma-
cokinetics and dose-dependent dynamics of insulin effects on midbrain
functional connectivity, ﬁrst a full-factorial design with the factors dose
(4 levels), time point (7 levels, 1 baseline condition and 6 post-
intervention time points) and BMI (2 levels) was set up in SPM. This
factorial design lends structure to examining the effects of dosage and
time while considering the BMI. In a second step, we set up a full-factorial
design with the factors dose (4 levels), time point (7 levels) and HOMA-IR
(2 levels) to analyse the effect of systemic insulin sensitivity. As results,
we only report ﬁndings that survived under family-wise-error (FWE)
correction at the cluster level (p< 0.05), with a cluster-deﬁning
threshold (CDT) of p< 0.001, across the whole-brain. Notably, under
this CDT, cluster-level correction ensures valid false positive rate control
(Eklund et al., 2016; Flandin and Friston, 2016). We found a signiﬁcant
cluster reﬂecting a three-way-interaction for intervention dose, time
point and HOMA-IR group in the ventromedial prefrontal cortex
(vmPFC). This three-way interaction indicates that an experimental ef-
fect exists, speciﬁcally, that the dosage-dependent modulation of tem-
poral trajectories of midbrain-vmPFC coupling differ across groups. Since
two participants had a median HOMA-IR and were thus assigned arbi-
trarily to the lower HOMA-IR group, we repeated the analysis after
omitting those two subjects and found qualitatively the same three-way
interaction. To further disentangle the nature of this complex interaction,
we extracted the parameter estimates of this cluster and separately per-
formed two-way ANOVAs for HOMA-IR groups testing the effect of dose
(4 levels) and time-point (7 levels). Next, at each time-point all doses
were compared against each other (Fig. 3 a). Multiple comparisons were
corrected using Tukey's method. In addition, to visualize insulin dose
effects across time beyond the ﬂuctuating placebo effects, we subtracted
the parameter estimates in the placebo condition from the corresponding
parameter estimates in the insulin condition (Fig. 3b). Given the
complexity of our three-way interaction and the many opportunities it
affords for testing effects at speciﬁc time points, we provide our full data
table in the Supplementary Information (Table S3) in order to enable
other scientists to analyse the dose-dependent trajectories in both groups
according to their speciﬁc question.
Other statistical analyses. The analyses of biochemical data and ratings
were assessed by linear mixed effect models using the R package ‘NLME’
3.1 (Pinheiro et al., 2017). Post-hoc comparisons were calculated using
the Tukey's procedure (R ‘LSMEANS’ package, Lenth, 2016).
3. Results
Neuroimaging data. We examined the modulation of midbrain (VTA/
SN) connectivity by intranasal administration of insulin in six time points
spread over an interval of 15–90min post-intervention (Fig. 1).
We did not detect a three-way interaction of interaction dose, time
point and BMI (lean and overweight individuals). By contrast, we found a
three-way interaction of intervention dose, time point, and peripheral
insulin sensitivity (reﬂected by HOMA-IR) for the functional coupling
between the VTA/SN complex and the ventromedial prefrontal cortex
(vmPFC; p¼ 0.005, FWE whole-brain cluster-level corrected, under a
cluster-deﬁning threshold of p< 0.001; see Methods; Fig. 2, Table S2).
Two participants did have a median HOMA-IR and were arbitrarily
assigned to the lower HOMA-IR group; omitting these subjects from the
analysis did not qualitatively affect this three-way interaction (vmPFC,
p¼ 0.048, whole-brain cluster-level corrected, under a cluster-deﬁning
threshold of p< 0.001). In other words, systemic insulin sensitivity
rather than body weight interacts with time-dependent modulation of
VTA/SN-functional connectivity by intranasal insulin.
The signiﬁcant three-way interaction indicates that the dosage-
dependent modulation of temporal trajectories of midbrain-vmPFC
Fig. 2. Modulation of functional connectivity by intranasal insulin. A three-way
interaction for dose, time and HOMA-IR revealed coupling between the
midbrain (VTA/SN) and the ventromedial prefrontal cortex (vmPFC, p¼ 0.005,
whole-brain cluster-level corrected, under a cluster-deﬁning threshold
of p< 0.001).
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coupling differs across groups. To disentangle this complex result, we
analysed the dose-by-time interaction post-hoc, separately for both
HOMA-IR groups (Fig. 3). For both the low (F(18,378)¼ 1.65, p¼ 0.046)
and the high HOMA-IR group (F(18,336)¼ 2.77, p¼ 0.0002) we found a
signiﬁcant dose-by-time interaction.
As illustrated in Fig. 3, the functional coupling between midbrain and
vmPFC in the low-HOMA-IR group showed a modulation for 40 I.U.
(placebo vs. 40 I.U. insulin, p¼ 0.031) and 160 I.U. (placebo vs. 160 I.U.
insulin, p¼ 0.012) of insulin at 25–35min post-intervention. The high
HOMA-IR group exhibited differences already in baseline condition
(placebo vs. 100 I.U. insulin p¼ 0.047) and a rather slow increase with
signiﬁcant modulation at 35–45min (40 I.U. vs. 160 I.U insulin,
p¼ 0.019) and 80–90min post-intervention (placebo vs. 40 I.U. insulin
p¼ 0.046, placebo vs. 100 I.U. insulin, p¼ 0.050). As explained above,
we provide the full data table in the Supplementary Information
(Table S3) to enable further exploration of this complex three-way
interaction according to speciﬁc research questions.
Biochemical data. To ensure adherence to overnight fasting and to
control for putative metabolic inﬂuences, we checked metabolic pa-
rameters and hormones in baseline conditions (i.e., prior to insulin
administration): None of these tests showed a signiﬁcant difference be-
tween testing days. High HOMA-IR was associated with higher serum
levels of insulin (F1,34¼ 24.32, p< 0.001; Fig. 4b), c-peptide
(F1,34¼ 13,30 p¼ 0.0009; Fig. 4c), as well as insulin-like growth factor 1
(IGF 1; F1,34¼ 10.54, p¼ 0.0026). Glucose, triglyceride and blood
cortisol levels did not differ between HOMA-IR groups.
Fig. 3. Dosage effect of intranasally administered insulin on VTA/SN to vmPFC connectivity in subjects with high peripheral insulin sensitivity and subjects with low
peripheral insulin sensitivity. a.) The time-by-dose interactions are provided for all doses including placebo. b.) Time-by-dose dynamics of insulin intervention
subtracted by parameter estimates in corresponding placebo conditions. x-axis denotes time points (time), y-axis refers to a measure of functional connectivity
(parameter estimate from a subject-wise regression model). Data are presented as mean SEM; þp< 0.05 for 40 I.U. vs. placebo; #p< 0.05 for 100 I.U. vs. placebo;
*p< 0.05 for 160 I.U. vs. placebo, Δp< 0.05 for 160 I.U vs. 40 I.U insulin; p-value adjustment for multiple comparisons using Tukey's procedure.
Fig. 4. Differences in peripheral insulin and c peptide levels. a.) HOMA-IR groups showed an equal distribution in BMI but differed in b.) baseline serum insulin level
and c.) baseline serum c-peptide level across testing days. Data are presented as means  SEM; **p < 0.01, ***p < 0.0001.
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To assess any potential spill-over of intranasally applied insulin into
circulation, we analysed the effect of intranasally administered insulin on
metabolic parameters and hormones by collecting blood samples 10, 50,
and 90min, respectively, after intervention. Analysing the effects of
intervention dose, time and peripheral insulin sensitivity, we found a
time-by-dose (insulin: F9,400¼ 19.30, p< 0.0001; c-peptide:
F9,398¼ 9.78, p< 0.0001), dose-by-HOMA-IR (insulin: F3,102¼ 3.27,
p¼ 0.0242; c-peptide: F3,102¼ 4.34, p¼ 0.0057) and time-by-HOMA-IR
interaction (insulin: F3,398¼ 5.8, p¼ 0.0006; c-peptide: F3,398¼ 7.42,
p¼ 0.0001) for insulin and c-peptide. Ten minutes after intranasal
administration of 100 (t¼ 6.81, p< 0.0001) and 160 I.U. of insulin
(t¼ 12.90, p< 0.0001), the serum insulin level increased signiﬁcantly,
suggesting a spill-over effect from the CNS to circulation (Suppl. Fig. S1).
The c-peptide level was analysed in addition, given its role in endogenous
insulin release: The higher the dose of intranasally applied insulin, the
sooner endogenous insulin production decreased. At 160 I.U. the c-pep-
tide level signiﬁcantly decreased after 10min (t¼3.58, p¼ 0.0016),
while at 40 I.U (t¼2.60, p¼ 0.011) and 100 I.U. (t¼ - 2.99, p¼ 0.005)
the level dropped after 50min intervention. The change in serum levels
of insulin had an impact on the glucose level; the latter showed an
interaction of time and dose (F9,402¼ 6.59, p< 0.0001). Ten minutes
(t¼4,59, p< 0.0001) and 50min (t¼3.83, p¼ 0.0007) after 160 I.U.
of insulin the glucose was signiﬁcantly decreased (see Supplementary
Material for further details).
Hunger, satiety and tiredness ratings. To control for differences in the
internal states between testing days, we instructed the participants to rate
hunger, satiety and tiredness immediately prior to the baseline fMRI
scan. The ratings were repeated 10, 50 and 90min after each interven-
tion: We tested the effect of intervention dose, time and HOMA-IR on all
three ratings. Hunger (F3,402¼ 17.49, p< 0.0001) and tiredness
(F3,402¼ 25.90, p< 0.0001) increased over time, and satiety rating
decreased over time (F3,402¼ 18.03, p< 0.0001) but the ratings were not
modulated by either insulin dose or HOMA-IR (Suppl. Fig. S2).
4. Discussion
This article provides a systematic analysis of the modulatory effects of
intranasally administered insulin on dopaminergic midbrain projections,
in two groups of volunteers with different levels of peripheral insulin
sensitivity.
The signiﬁcant three-way interaction detected by our whole-brain
analysis suggests that the time- and dose-dependent effects of insulin
on the functional connectivity of the midbrain to vmPFC depended on
systemic insulin sensitivity. This signiﬁcantly extends previous ﬁndings
that the activation of dopaminergic pathways and reward signalling by
food cues and actual food intake becomes dysregulated with increasing
body weight (de Araujo et al., 2008; Stice et al., 2009, 2010; Wang et al.,
2014) and that reward-related and prefrontal neurocircuitry showed
reduced insulin responsiveness with increasing BMI (Kullmann et al.,
2013). It is important to emphasize, that our results are in line with
recent human studies emphasizing that peripheral insulin sensitivity is a
better predictor for altered dopaminergic signalling than BMI (Eckstrand
et al., 2017; Eisenstein et al., 2015; Tiedemann et al., 2017). This sug-
gests that changes in systemic insulin sensitivity affect midbrain circuits –
an interpretation of relevance for the suggestion that insulin (and other
humoral factors) provides a nutrient signal that increases incentive
salience and motivational drive to obtain food under different metabolic
states (Lockie and Andrews, 2013).
In particular midbrain connections to vmPFC are crucial for reward
processing and value-based decision making (Jocham et al., 2011). The
vmPFC has been associated with encoding value (Rushworth et al.,
2012), a construct of central importance for inhibitory control (Appel-
hans, 2009; Hare et al., 2009). The values encoded by vmPFC, along with
conﬁdence estimates (Lebreton et al., 2015), likely pertain to a large set
of actions and stimuli, including the value of health and taste attributes of
foods (Medic et al., 2016). Hence, our ﬁndings are of interest to recent
suggestions that obesity may be characterized by a shift in how the
availability of food inﬂuences value-based decision-making (Medic et al.,
2016).
To understand the nature of the interaction between time, dose and
HOMA-IR, we extracted the parameter estimates from the signiﬁcant
cluster. Interestingly, the lowest (40 I.U.) and highest (160 I.U.) dose of
insulin in our study seem tomodulate midbrain-vmPFC connectivity with
peaks at 30min after intervention in participants with high systemic
insulin sensitivity (Fig. 3). While surprising at ﬁrst glance, this ﬁnding is
in line with other human studies reporting central effects of insulin for
low as well as for fairly high doses (Suppl. Table S1). Also studies in mice
showed a differentiated dose-speciﬁc action of insulin on neuronal cir-
cuitries with an elevation of reward thresholds by insulin (directly
applied in the VTA) for low doses; by contrast, higher doses modulated
food intake without affecting reward-related behaviour (Bruijnzeel et al.,
2011). We can only speculate about the underlying mechanisms, but it is
possible that the effects of insulin on DA receptor function in both VTA
and dopaminoceptive target regions, with consequences for the func-
tional strengths of projections from midbrain, follow a nonlinear
(possibly “U-shape”) dose-response relationship, as has been observed for
other aspects of insulin function.
The peak at 25–35min coincided with a previously reported signiﬁ-
cant change of insulin level in the CSF after intranasal application of the
same insulin dose (Born et al., 2002). Born et al. (2002) also reported that
after an hour the CSF insulin level had not returned to baseline. Trans-
portation delays after intranasal administration and insulin's multiple
effects on DA neurons may also underlie the particular time course we
observed (Mittal et al., 2014). Insulin transport to the brain occurs via
multiple pathways with different transmission times: (1) intraneuronal
transport via the olfactory nerve that takes hours (Born et al., 2002); (2)
perineuronal transport along the olfactory and trigeminal nerves within
30min (Renner et al., 2012); and (3) rapid transport within cerebral
perivascular spaces (Lochhead et al., 2015). Once insulin has reached the
midbrain, however, it can have various effects on dopaminergic neurons.
Collectively, our ﬁndings are thus compatible with the idea that in-
sulin regulates feeding behaviour through its action on midbrain dopa-
mine neurons and the ensuing consequences for reward-related and
motivational processes (Davis et al., 2010; Kenny, 2011b). A methodo-
logical caveat worth pointing out is that a direct link between functional
connectivity of midbrain and changes in dopaminergic signalling is not
yet conclusively established in humans. Our approach, which uses
functional connectivity as a proxy readout for dopaminergic projections,
will thus require further validation.
In conclusion, for the ﬁrst time we provide an assessment of the time-
and dose-dependent effects of insulin on functional connectivity of the
dopaminergic midbrain – and suggest that these effects varied with pre-
existing difference in insulin sensitivity. Our ﬁndings may provide useful
guidance for future studies that employ intranasal insulin administration
and face the question what insulin dose should be chosen and when
functional readouts should be obtained. Furthermore, our results suggest
that altered insulin sensitivity impacts on the function of the dopami-
nergic midbrain and might underlie the dysregulation of reward-related
and motivational behaviour in obesity and diabetes.
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